Navigation Links
NPS Pharmaceuticals to Report Third Quarter 2007 Financial Results and Nycomed Decision on GATTEX(TM) Partnership on November 1, 2007
Date:10/25/2007

BEDMINSTER, N.J., Oct. 25 /PRNewswire-FirstCall/ -- NPS Pharmaceuticals, Inc. (Nasdaq: NPSP) announced today that it will report its third quarter financial results and Nycomed's decision whether to proceed with ex-U.S. development and commercialization of GATTEX(TM) (teduglutide) on Thursday, November 1, 2007. NPS expects to receive notification from Nycomed at the end of this month regarding Nycomed's plans to partner with NPS on the development of GATTEX(TM) (teduglutide) outside North America. The announcement will be followed by a conference call and webcast at 5:00 p.m. EDT, featuring Dr. Anthony Coles, president and CEO, and other members of the NPS executive team.

To participate in the conference call, dial (866) 770-7051 and use passcode 53288322. International callers may dial (617) 213-8064, using the same passcode. In addition, live audio of the conference call will be simultaneously broadcast over the Internet and may be accessed on the company's web site (http://www.npsp.com).

If you are unable to participate in the live call, a replay will be available at (888) 286-8010, with passcode 16038876, until midnight EST, November 15, 2007. International callers may access the replay by dialing (617) 801-6888, using the same passcode. The webcast will also be available on the NPS website for the same period of time.

About NPS Pharmaceuticals

NPS Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of small molecules and recombinant proteins as drugs, primarily for the treatment of metabolic, bone and mineral, and central nervous system disorders. The company has drug candidates in various stages of clinical development. Additional information is available on the company's website, http://www.npsp.com.


'/>"/>
SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. Assess the In Vivo Activation of Signal Transduction Pathways with PathDetect Reporting Systems
4. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
5. Signal Transduction Reporting Systems Using Cis-Acting Enhancer Elements
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. Versatile Reporter Vectors for Monitoring Viral Transduction
8. In Vivo Signal Transduction Pathway Reporting Systems
9. Improved Vectors for PathDetect Trans-Reporting Systems
10. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
11. Cis-Reporting System Monitors Intracellular Calcium Mobilization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... , May 19, 2016  AdvancedFlow Systems ... Inc. (AGI), based out of Maple ... Biogas Ltd. to its existing portfolio of contract ... agreement. AFS along with its sister companies Surround ... a vertically integrated industrial group that specializes in ...
(Date:5/19/2016)... City, KS (PRWEB) , ... May 19, 2016 ... ... biomarker contract research organization (CRO) has welcomed Abu Siddiqui as Director, Large Molecule ... managing and executing biologics, vaccine and translational biomarker discovery studies for preclinical and ...
(Date:5/19/2016)... , May 19, 2016 - ... sessione orale durante il 52 ° ... 8006)    - Le conclusioni dello studio ... i pazienti trattati, di cui il 90% presenta una d ... mesi o più. Il settantadue per cento dei pazienti ha ...
(Date:5/18/2016)... ... 2016 , ... Shimadzu Scientific Instruments announces its sponsorship of ... two-day camp will take place annually starting June 2016. It will provide qualifying ... preparation for a university academic program. , The laboratory- and technology-focused camp ...
Breaking Biology Technology:
(Date:5/3/2016)... 3, 2016  Neurotechnology, a provider of high-precision ... Automated Biometric Identification System (ABIS) , a complete ... MegaMatcher ABIS can process multiple complex biometric transactions ... of fingerprint, face or iris biometrics. It leverages ... and MegaMatcher Accelerator , which have been ...
(Date:4/26/2016)... DUBLIN , April 27, 2016 ... of the  "Global Multi-modal Biometrics Market 2016-2020"  report ... ) , The analysts forecast ... a CAGR of 15.49% during the period 2016-2020.  ... a number of sectors such as the healthcare, ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):